Logo do repositório
 
Publicação

Hepatitis C virus infection epidemiology among people who inject drugs in europe: A systematic review of data for scaling up treatment and prevention

2014Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorWiessing, L.
dc.contributor.authorFerri, M.
dc.contributor.authorGrady, B.
dc.contributor.authorKantzanou, M.
dc.contributor.authorSperle, I.
dc.contributor.authorCullen, K.J.
dc.contributor.authorHatzakis, A.
dc.contributor.authorPalladino, Claudia
dc.date.accessioned2025-08-14T16:56:02Z
dc.date.available2025-08-14T16:56:02Z
dc.date.issued2014
dc.date.updated2023-02-09T15:18:57Z
dc.description© 2014 Wiessing et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.pt_PT
dc.description.abstractBackground People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment options are improving and may enhance prevention; however access for PWID may be poor. The availability in the literature of information on seven main topic areas (incidence, chronicity, genotypes, HIV co-infection, diagnosis and treatment uptake, and burden of disease) to guide HCV treatment and prevention scale-up for PWID in the 27 countries of the European Union is systematically reviewed. Methods and Findings We searched MEDLINE, EMBASE and Cochrane Library for publications between 1 January 2000 and 31 December 2012, with a search strategy of general keywords regarding viral hepatitis, substance abuse and geographic scope, as well as topic-specific keywords. Additional articles were found through structured email consultations with a large European expert network. Data availability was highly variable and important limitations existed in comparability and representativeness. Nine of 27 countries had data on HCV incidence among PWID, which was often high (2.7-66/100 person-years, median 13, Interquartile range (IQR) 8.7–28). Most common HCV genotypes were G1 and G3; however, G4 may be increasing, while the proportion of traditionally ‘difficult to treat’ genotypes (G1+G4) showed large variation (median 53, IQR 43–62). Twelve countries reported on HCV chronicity (median 72, IQR 64–81) and 22 on HIV prevalence in HCV-infected PWID (median 3.9%, IQR 0.2–28). Undiagnosed infection, assessed in five countries, was high (median 49%, IQR 38–64), while of those diagnosed, the proportion entering treatment was low (median 9.5%, IQR 3.5–15). Burden of disease, where assessed, was high and will rise in the next decade. Conclusion Key data on HCV epidemiology, care and disease burden among PWID in Europe are sparse but suggest many undiagnosed infections and poor treatment uptake. Stronger efforts are needed to improve data availability to guide an increase in HCV treatment among PWID.pt_PT
dc.description.sponsorshipEMCDDA has funded this study through seven partial contracts with AH, MP, PV, JL, VH, and CM to carry out the tasks as specified for these authors in the author contributions. EMCDDA has coordinated and carried out the tasks in this study as specified for LW in the author contributions. LW had full access to all the data in the study and had final responsibility for the decision to submit for publication. Lucy Platt, Bethan Mcdonald, and Andrea Low are members of the EMCDDA DRID group who were partly funded by the Bill and Melinda Gates Foundation funded HIV Modelling Consortium to undertake a systematic review of HIV and HCV co-infection which fed into the co-infection review included here. The Bill and Melinda Gates Foundation funded HIV Modelling Consortium had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationWiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis c virus infection epidemiology among people who inject drugs in europe: a systematic review of data for scaling up treatment and prevention. PLOS ONE [Internet]. 28 de julho de 2014;9(7):e103345. Disponível em: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103345pt_PT
dc.identifier.doi10.1371/journal.pone.0103345pt_PT
dc.identifier.eid2-s2.0-84904987089
dc.identifier.slugcv-prod-1185530
dc.identifier.urihttp://hdl.handle.net/10400.5/102917
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherPLoSpt_PT
dc.relation.publisherversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103345pt_PT
dc.titleHepatitis C virus infection epidemiology among people who inject drugs in europe: A systematic review of data for scaling up treatment and preventionpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue7pt_PT
oaire.citation.startPagee103345pt_PT
oaire.citation.titlePLoS ONEpt_PT
oaire.citation.volume9pt_PT
person.familyNamePalladino
person.givenNameClaudia
person.identifier.ciencia-id721D-6851-20D5
person.identifier.orcid0000-0002-8148-0928
rcaap.cv.cienciaid721D-6851-20D5 | Claudia Palladino
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication96b2385b-89f4-428a-9ab2-6fdb5514541b
relation.isAuthorOfPublication.latestForDiscovery96b2385b-89f4-428a-9ab2-6fdb5514541b

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
2014_HCV_epidemiology_in_PWID_Wiessing_Palladino_PONE.pdf
Tamanho:
983.3 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FF - CiênciaVitae - Faculdade de Farmácia